1.82 USD
0 (0%)
MYMD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 190 industry peers in the Pharmaceuticals industry. The financial health of MYMD is average, but there are quite some concerns on its profitability. MYMD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- MYMD had negative earnings in the past year.
- In the past year MYMD has reported a negative cash flow from operations.
1.2 Ratios
- MYMD has a Return On Assets of -32.43%. This is comparable to the rest of the industry: MYMD outperforms 51.55% of its industry peers.
- With a Return On Equity value of -43.95%, MYMD perfoms like the industry average, outperforming 59.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.43% | ||
| ROE | -43.95% | ||
| ROIC | N/A |
ROA(3y)-84.95%
ROA(5y)-85.91%
ROE(3y)-93.54%
ROE(5y)-101.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for MYMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- MYMD has more shares outstanding than it did 1 year ago.
- MYMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- MYMD has an Altman-Z score of -7.99. This is a bad value and indicates that MYMD is not financially healthy and even has some risk of bankruptcy.
- MYMD has a worse Altman-Z score (-7.99) than 73.20% of its industry peers.
- MYMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.99 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- MYMD has a Current Ratio of 1.71. This is a normal value and indicates that MYMD is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.71, MYMD is doing worse than 71.65% of the companies in the same industry.
- A Quick Ratio of 1.71 indicates that MYMD should not have too much problems paying its short term obligations.
- MYMD has a worse Quick ratio (1.71) than 67.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.71 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
- MYMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.63%, which is quite impressive.
EPS 1Y (TTM)52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MYMD. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for MYMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYMD PHARMACEUTICALS INC / MYMD FAQ
What is the ChartMill fundamental rating of MYMD PHARMACEUTICALS INC (MYMD) stock?
ChartMill assigns a fundamental rating of 2 / 10 to MYMD.
What is the valuation status for MYMD stock?
ChartMill assigns a valuation rating of 0 / 10 to MYMD PHARMACEUTICALS INC (MYMD). This can be considered as Overvalued.
How profitable is MYMD PHARMACEUTICALS INC (MYMD) stock?
MYMD PHARMACEUTICALS INC (MYMD) has a profitability rating of 1 / 10.
How sustainable is the dividend of MYMD PHARMACEUTICALS INC (MYMD) stock?
The dividend rating of MYMD PHARMACEUTICALS INC (MYMD) is 0 / 10 and the dividend payout ratio is 0%.